Clovis Oncology (NASDAQ:CLVS) reported Q1 EPS of ($0.44), $0.01 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $34.2 million versus the consensus estimate of $36.97 million.
Clovis Oncology (NASDAQ:CLVS) reported Q1 EPS of ($0.44), $0.01 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $34.2 million versus the consensus estimate of $36.97 million.